PRV-3279-2a Trial in Systemic Lupus
Part of paid clinical trials in Apple Valley, California.
- Sponsor
- Provention Bio, a Sanofi Company
- Study ID
- NCT05087628
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- PRV-3279 — BIOLOGICALBi-specific antibody-based molecule
- Placebo — OTHERPlacebo
Study Details
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
Key Dates
- First listed
- Oct 21, 2021
- Start date
- Jan 20, 2022
- Status verified
- Mar 2026
- Primary completion
- May 14, 2024
- Completion
- Jun 24, 2024
Study Design
- Enrollment
- 28 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: PRV-3279Sterile solution for intravenous administration, every 4 weeks
- Experimental: PlaceboSterile solution for intravenous administration, every 4 weeks
Primary Outcome Measure
Percentage of Participants Who Maintained the Improvement in Systemic Lupus Erythematosus (SLE) Disease Activity From Baseline to Week 24 [ Time Frame: Baseline (Day 1) to Week 24 ]
Locations (22)
Find similar trials in Apple Valley, CA
By condition
By specialty
By research site
Medvin Clinical Research - Apple Valley· Apple Valley, CAMedvin Clinical Research - Covina - West San Bernardino Road· Covina, CAUniversity of California San Diego - La Jolla· La Jolla, CAFacey Medical Group - Los Angeles· Los Angeles, CAUniversity of California Los Angeles Medical Center· Los Angeles, CADesert Medical Advances· Rancho Mirage, CA
Related Studies
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)Recruiting · Hospital for Special Surgery, New York · New York, New York
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusPHASE3 · Enrolling By Invitation · UCB Biopharma SRL · Birmingham, Alabama